Stocks and Investing Stocks and Investing
Fri, February 2, 2018
Thu, February 1, 2018

Geoff Meacham Maintained (VRTX) at Buy with Increased Target to $200 on, Feb 1st, 2018


Published on 2024-10-26 02:26:39 - WOPRAI, Geoff Meacham
  Print publication without navigation


Geoff Meacham of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $180 to $200 on, Feb 1st, 2018.

Geoff, nor any peers, have made any analyst calls on VRTX in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources